Selected article for: "IgG increase and SARS infection"
Author: Korodi, M.; Rakosi, K.; Jenei, Z.; Hudak, G.; Horvath, I.; Kakes, M.; Dallos-Fejer, K.; Simai, E.; Staver, N.; Briciu, V.; Lupse, M.; Flonta, M.; Almas, A.; Dana, P.; Terza, L.-M.; Fejer, S.
Title: Longitudinal determination of mRNA-vaccination induced strongly binding SARS-CoV-2 IgG antibodies in a cohort of healthcare workers with and without prior exposure to the novel coronavirus
  • Cord-id: sy6zghaf
  • Document date: 2021_3_24
    • ID: sy6zghaf
    Snippet: Mass vaccination against the disease caused by the novel coronavirus (COVID-19) is a crucial step in slowing the spread of SARS-CoV-2. The BioNTech/Pfizer (BNT162b2) vaccine has been shown to induce strong immune responses among the vaccinated population. Measuring SARS-CoV-2 anti-spike protein IgG levels is a clinically convenient way to estimate post-vaccination humoral immune responses, but only limited data exists about its short- and long-term dynamics. We present a longitudinal analysis of
    Document: Mass vaccination against the disease caused by the novel coronavirus (COVID-19) is a crucial step in slowing the spread of SARS-CoV-2. The BioNTech/Pfizer (BNT162b2) vaccine has been shown to induce strong immune responses among the vaccinated population. Measuring SARS-CoV-2 anti-spike protein IgG levels is a clinically convenient way to estimate post-vaccination humoral immune responses, but only limited data exists about its short- and long-term dynamics. We present a longitudinal analysis of post-vaccination IgG levels in a cohort of 122 healthcare workers vaccinated with BNT162b2 with weekly follow-up until 35 days past the first dose and results of the first monthly follow-up after that for a subset of these. This prospective, multicenter cohort study consists of two periods for short-term and long-term evaluation of post-vaccination IgG levels. Tests were carried out on 666 samples from 122 participants, using in-house anti-spike 1 and anti-nucleocapsid IgG ELISA assays and a commercial, combined version of these. Participants with previous SARS-CoV-2 infection mount a quick immune response, reaching peak IgG levels two weeks after vaccination. In contrast, the corresponding IgG levels for previously uninfected participants increase gradually, changing abruptly after the booster dose. Overall higher IgG levels are maintained for the previously infected group 35-70 days after vaccination, and we observe age-dependence of immune response as well. Our results show a robust humoral immune response mounting gradually after the first vaccine dose for the uninfected group, and a much stronger immune response within 7-14 days after the first dose for the previously infected group.

    Search related documents:
    Co phrase search for related documents
    • acquire immunity and long follow: 1
    • activation pre and acute respiratory syndrome coronavirus: 1
    • acute respiratory syndrome coronavirus and long follow: 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25
    • acute respiratory syndrome coronavirus and long last immunity: 1
    • acute respiratory syndrome coronavirus and long term follow study: 1
    • acute respiratory syndrome coronavirus and long term immune response: 1, 2, 3, 4, 5
    • acute respiratory syndrome coronavirus and long term protection: 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22
    • acute respiratory syndrome coronavirus and longitudinal evaluation: 1, 2
    • acute respiratory syndrome coronavirus and longitudinal increase: 1, 2
    • acute respiratory syndrome coronavirus and longitudinal monitoring: 1, 2, 3